Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction

Megan Melody; Emily Butts; David Menke; Kevin Landolfo; Keith Oken; Taimur Sher; Sharad Khurana

doi:10.1016/j.lrr.2020.100228

Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction

Megan Melody, Emily Butts, David Menke, Kevin Landolfo, Keith Oken, Taimur Sher, Sharad Khurana

Research output: Contribution to journal › Article › peer-review

Abstract

Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post-operative myelomonocytic leukemoid reaction (PO-MMLR), effectively treated with tocilizumab. Although, further studies are needed to validate the effectiveness of tocilizumab in management of PO-MMLR, this case serves to provide a new management approach in treatment of this rare but lethal syndrome with no standardized treatment options.

Original language	English (US)
Article number	100228
Journal	Leukemia Research Reports
Volume	14
DOIs	https://doi.org/10.1016/j.lrr.2020.100228
State	Published - Jan 2020

Keywords

Chronic myelomonocytic leukemia
Leukemoid reaction
Systemic inflammatory response
Tocilizumab

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.lrr.2020.100228

Cite this

@article{a506167ce1c14f66ae1f021ac02d6d3f,

title = "Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction",

abstract = "Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post-operative myelomonocytic leukemoid reaction (PO-MMLR), effectively treated with tocilizumab. Although, further studies are needed to validate the effectiveness of tocilizumab in management of PO-MMLR, this case serves to provide a new management approach in treatment of this rare but lethal syndrome with no standardized treatment options.",

keywords = "Chronic myelomonocytic leukemia, Leukemoid reaction, Systemic inflammatory response, Tocilizumab",

author = "Megan Melody and Emily Butts and David Menke and Kevin Landolfo and Keith Oken and Taimur Sher and Sharad Khurana",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = jan,

doi = "10.1016/j.lrr.2020.100228",

language = "English (US)",

volume = "14",

journal = "Leukemia Research Reports",

issn = "2213-0489",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction

AU - Melody, Megan

AU - Butts, Emily

AU - Menke, David

AU - Landolfo, Kevin

AU - Oken, Keith

AU - Sher, Taimur

AU - Khurana, Sharad

PY - 2020/1

Y1 - 2020/1

N2 - Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post-operative myelomonocytic leukemoid reaction (PO-MMLR), effectively treated with tocilizumab. Although, further studies are needed to validate the effectiveness of tocilizumab in management of PO-MMLR, this case serves to provide a new management approach in treatment of this rare but lethal syndrome with no standardized treatment options.

AB - Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post-operative myelomonocytic leukemoid reaction (PO-MMLR), effectively treated with tocilizumab. Although, further studies are needed to validate the effectiveness of tocilizumab in management of PO-MMLR, this case serves to provide a new management approach in treatment of this rare but lethal syndrome with no standardized treatment options.

KW - Chronic myelomonocytic leukemia

KW - Leukemoid reaction

KW - Systemic inflammatory response

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=85096164279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096164279&partnerID=8YFLogxK

U2 - 10.1016/j.lrr.2020.100228

DO - 10.1016/j.lrr.2020.100228

M3 - Article

AN - SCOPUS:85096164279

SN - 2213-0489

VL - 14

JO - Leukemia Research Reports

JF - Leukemia Research Reports

M1 - 100228

ER -

Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this